Display options
Cite
Okomo-Adhiambo M, Sleeman K, Ballenger K, et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses. 2010;2(10):2269-89doi: 10.3390/v2102269.
Okomo-Adhiambo, M., Sleeman, K., Ballenger, K., Nguyen, H. T., Mishin, V. P., Sheu, T. G., Smagala, J., Li, Y., Klimov, A. I., & Gubareva, L. V. (2010). Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses, 2(10), 2269-89. https://doi.org/10.3390/v2102269
Okomo-Adhiambo, Margaret, et al. "Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective." Viruses vol. 2,10 (2010): 2269-89. doi: https://doi.org/10.3390/v2102269
Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses. 2010 Oct;2(10):2269-89. doi: 10.3390/v2102269. Epub 2010 Oct 13. PMID: 21994620; PMCID: PMC3185571.
Copy Download .nbib Format: NLM
Share it on

Viruses. 2010 Oct;2(10):2269-89. doi: 10.3390/v2102269. Epub 2010 Oct 13.

Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.

Viruses

Margaret Okomo-Adhiambo, Katrina Sleeman, Kristina Ballenger, Ha T Nguyen, Vasiliy P Mishin, Tiffany G Sheu, James Smagala, Yan Li, Alexander I Klimov, Larisa V Gubareva

Affiliations

  1. Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G16, Atlanta, GA 30333, USA; E-Mails: [email protected] (M.O.-A.); [email protected] (K.S.); [email protected] (K.B.); [email protected] (H.T.N.); [email protected] (V.P.M.); [email protected] (T.G.S.); [email protected] (J.S.); [email protected] (A.I.K.).

PMID: 21994620 PMCID: PMC3185571 DOI: 10.3390/v2102269

Abstract

Neuraminidase inhibitors (NAIs) are vital in managing seasonal and pandemic influenza infections. NAI susceptibilities of virus isolates (n = 5540) collected during the 2008-2009 influenza season were assessed in the chemiluminescent neuraminidase inhibition (NI) assay. Box-and-whisker plot analyses of log-transformed IC(50)s were performed for each virus type/subtype and NAI to identify outliers which were characterized based on a statistical cutoff of IC(50) >3 interquartile ranges (IQR) from the 75(th) percentile. Among 1533 seasonal H1N1 viruses tested, 1431 (93.3%) were outliers for oseltamivir; they all harbored the H275Y mutation in the neuraminidase (NA) and were reported as oseltamivir-resistant. Only 15 (0.7%) of pandemic 2009 H1N1 viruses tested (n = 2259) were resistant to oseltamivir. All influenza A(H3N2) (n = 834) and B (n = 914) viruses were sensitive to oseltamivir, except for one A(H3N2) and one B virus, with D151V and D197E (D198E in N2 numbering) mutations in the NA, respectively. All viruses tested were sensitive to zanamivir, except for six seasonal A(H1N1) and several A(H3N2) outliers (n = 22) which exhibited cell culture induced mutations at residue D151 of the NA. A subset of viruses (n = 1058) tested for peramivir were sensitive to the drug, with exception of H275Y variants that exhibited reduced susceptibility to this NAI. This study summarizes baseline susceptibility patterns of seasonal and pandemic influenza viruses, and seeks to contribute towards criteria for defining NAI resistance.

Keywords: Oseltamivir; pandemic H1N1; peramivir; seasonal influenza A and B; zanamivir

References

  1. Antiviral Res. 2010 Feb;85(2):381-8 - PubMed
  2. MMWR Morb Mortal Wkly Rep. 2008 Jun 27;57(25):692-7 - PubMed
  3. Avian Dis. 2003;47(3 Suppl):1141-4 - PubMed
  4. Antimicrob Agents Chemother. 2003 Jul;47(7):2264-72 - PubMed
  5. Antimicrob Agents Chemother. 2010 Mar;54(3):1102-10 - PubMed
  6. Lancet. 2005 Oct 1;366(9492):1175-81 - PubMed
  7. Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92 - PubMed
  8. Anal Biochem. 2000 May 1;280(2):291-300 - PubMed
  9. Emerg Infect Dis. 2009 Feb;15(2):155-62 - PubMed
  10. Tohoku J Exp Med. 2008 Feb;214(2):113-20 - PubMed
  11. J Virol Methods. 2010 Oct;169(1):47-51 - PubMed
  12. J Infect Dis. 2007 Jul 15;196(2):249-57 - PubMed
  13. Annu Rev Med. 2008;59:397-413 - PubMed
  14. Antiviral Res. 2009 Sep;83(3):290-7 - PubMed
  15. J Clin Microbiol. 2003 Feb;41(2):742-50 - PubMed
  16. J Virol. 1993 Jun;67(6):2972-80 - PubMed
  17. J Virol. 2010 Jul;84(13):6769-81 - PubMed
  18. Antimicrob Agents Chemother. 2005 Nov;49(11):4515-20 - PubMed
  19. J Virol. 2009 Oct;83(20):10366-73 - PubMed
  20. Clin Infect Dis. 2007 Jan 15;44(2):197-202 - PubMed
  21. Antimicrob Agents Chemother. 2010 Sep;54(9):3671-7 - PubMed
  22. Antimicrob Agents Chemother. 2006 Jul;50(7):2395-402 - PubMed
  23. MMWR Morb Mortal Wkly Rep. 2009 May 1;58(16):435-7 - PubMed
  24. Antivir Ther. 2009;14(6):751-61 - PubMed
  25. J Clin Virol. 2010 Jan;47(1):23-8 - PubMed
  26. J Clin Virol. 2008 Jan;41(1):13-9 - PubMed
  27. J Clin Virol. 2010 Jan;47(1):34-7 - PubMed
  28. Emerg Infect Dis. 2008 Nov;14(11):1809-10 - PubMed
  29. Anal Biochem. 1979 Apr 15;94(2):287-96 - PubMed
  30. Antiviral Res. 2005 Oct;68(1):43-8 - PubMed
  31. MMWR Morb Mortal Wkly Rep. 2009 Feb 13;58(5):115-9 - PubMed
  32. Virus Res. 2004 Jul;103(1-2):195-7 - PubMed
  33. Antiviral Res. 2004 Apr;62(1):37-45 - PubMed
  34. Emerg Infect Dis. 2009 Apr;15(4):552-60 - PubMed
  35. Euro Surveill. 2008 Jan 31;13(5): - PubMed
  36. Antimicrob Agents Chemother. 2006 May;50(5):1872-4 - PubMed
  37. MMWR Morb Mortal Wkly Rep. 2009 Apr 17;58(14):369-74 - PubMed
  38. Rev Med Virol. 2000 Jan-Feb;10(1):45-55 - PubMed
  39. Antiviral Res. 2009 Jan;81(1):16-24 - PubMed

Publication Types